Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · IEX Real-Time Price · USD
19.92
+0.98 (5.17%)
At close: Jul 19, 2024, 4:00 PM
19.99
+0.07 (0.35%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Castle Biosciences Revenue
Castle Biosciences had revenue of $250.73M in the twelve months ending March 31, 2024, with 64.71% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $72.97M with 73.59% year-over-year growth. In the year 2023, Castle Biosciences had annual revenue of $219.79M with 60.38% growth.
Revenue (ttm)
$250.73M
Revenue Growth
+64.71%
P/S Ratio
2.19
Revenue / Employee
$411,025
Employees
610
Market Cap
549.94M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
Dec 31, 2019 | 51.87M | 29.08M | 127.62% |
Dec 31, 2018 | 22.79M | 9.03M | 65.67% |
Dec 31, 2017 | 13.75M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCSTL News
- 7 days ago - Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 - Business Wire
- 11 days ago - Castle Biosciences Honored with Top Workplaces Awards - Business Wire
- 13 days ago - Top 5 Health Care Stocks That May Explode In July - Benzinga
- 4 weeks ago - Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher® Test - Business Wire
- 4 weeks ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner - Business Wire
- 7 weeks ago - Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance - Business Wire
- 7 weeks ago - New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis - Business Wire